Bausch Health Companies (TSE:BHC) Posts Quarterly Earnings Results

Bausch Health Companies (TSE:BHC) announced its quarterly earnings results on Wednesday. The company reported C$1.79 earnings per share for the quarter, FiscalAI reports. The company had revenue of C$4.05 billion for the quarter. Bausch Health Companies had a positive return on equity of 120.43% and a negative net margin of 13.54%.

Bausch Health Companies Stock Up 28.5%

BHC stock opened at C$8.43 on Friday. Bausch Health Companies has a 12 month low of C$6.10 and a 12 month high of C$11.97. The company has a market cap of C$3.15 billion, a price-to-earnings ratio of -2.60, a PEG ratio of 0.21 and a beta of 0.97. The company has a current ratio of 1.32, a quick ratio of 0.58 and a debt-to-equity ratio of -1,009.96. The firm has a 50-day moving average of C$6.97 and a two-hundred day moving average of C$7.56.

Trending Headlines about Bausch Health Companies

Here are the key news stories impacting Bausch Health Companies this week:

• Positive Sentiment: Quarterly beat and guidance increase: Bausch Health reported quarterly revenue of approximately C$4.05 billion and adjusted EPS of C$1.79. The results exceeded market expectations, while management increased its guidance, improving investor confidence in the company’s earnings trajectory. Bausch Health posts a record rally after Q2 beat, guidance hike
• Positive Sentiment: Revenue and earnings exceeded estimates: Reports characterized the second-quarter results as a revenue and earnings beat, supporting the view that Bausch Health’s operating performance is improving and helping drive the stock’s increase. Bausch Health Rises After Q2 Earnings, Revenue Beat Estimates
• Neutral Sentiment: Profitability remains mixed: Despite the reported quarterly EPS, Bausch Health continues to post a negative net margin, underscoring ongoing financial and balance-sheet risks. Investors may focus on whether the improved results can be sustained.
• Negative Sentiment: Longer-term analyst estimates were trimmed: Zacks Research modestly reduced its EPS forecasts for several future periods, including fiscal 2027 to $5.06 from $5.10 and fiscal 2028 to $4.26 from $4.34. Quarterly estimates were also lowered slightly. These revisions suggest some caution about the company’s longer-term earnings growth, although they were overshadowed by the current-quarter beat and higher guidance.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group upgraded shares of Bausch Health Companies to a “hold” rating in a research report on Wednesday, July 22nd. Three analysts have rated the stock with a Hold rating, According to MarketBeat, the company has an average rating of “Hold”.

Bausch Health Companies Company Profile

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.